logo
Unsaturated fats may not always be anti-inflammatory, study finds

Unsaturated fats may not always be anti-inflammatory, study finds

Unsaturated fats, such as those found in oily fish, nuts, seeds, avocados, and olive oil, are recommended as part of a healthful diet.Studies have linked these fatty acids to reduced levels of inflammation and lowered LDL ('bad') cholesterol.However, a new study suggests that both omega-3 and omega-6 polyunsaturated fatty acids (PUFAs) are linked to increased levels of some inflammatory markers in the blood.Oily fish, nuts, seeds, avocados, and olive oil are all advocated as part of a healthful diet, mostly because of their high concentrations of unsaturated fatty acids. Studies suggest that unsaturated fatty acids, particularly omega-3, may reduce both inflammation, and levels of low-density lipoprotein, LDL or 'bad' cholesterol, which is linked to heart disease.However, a new study has suggested that polyunsaturated fatty acids may actually increase levels of some inflammatory biomarkers in the blood plasma.The research, which is published in The International Journal of Epidemiology, found that both omega-3 and omega-6 polyunsaturated fatty acids (PUFAs) were associated with raised levels of glycoprotein acetyls (GlycA), biomarkers associated with increased cardiovascular risk.Links to inflammatory biomarkers in the bloodThe researchers carried out their primary analysis on 2,802 participants from the Avon Longitudinal Study of Parents and Children (ALSPAC) birth cohort, which recruited a total of 14, 541 pregnant women residing in southwest England in 1991 and 1992, and has followed them and their offspring since then. They replicated their analysis using data from 12,401 participants in the UK Biobank.'Using two large datasets, ALSPAC and the UK Biobank, along with a genetic technique called Mendelian randomization, the researchers examined whether these fats cause changes in inflammation, rather than just being associated with it, exploring actual causality. This approach is especially powerful because it helps minimize the usual confounding factors found in nutrition studies, such as lifestyle or other dietary habits. In other words, the researchers went beyond asking who has more inflammation and what they eat and instead tried to determine whether the fats themselves were directly responsible.'— Thomas M. Holland, MD, MS, physician-scientist and assistant professor at the RUSH Institute for Healthy Aging, RUSH University, College of Health Sciences, Chicago, who was not involved in the study.The researchers assessed the ALSPAC offspring after 24 years. In their analysis, they controlled for household social class at birth, maternal highest education qualification at birth, maternal and paternal smoking status during pregnancy, offspring sex at birth, type of drinker at age 24 , type of smoker at 24 , and at age in months at 24-year clinic.Daisy Crick, corresponding author, Institute for Molecular Bioscience, Queensland University, Australia, and MRC Integrative Epidemiology Unit, The University of Queesland, Australia, explained their research:'Dietary fatty acids were measured using levels of DHA, total omega-3 LA, total omega-6, and the omega-6:omega-3 ratio found in the blood. Inflammation was measured using substances in the blood called biomarkers and specifically we used the biomarkers C-reactive protein (CRP), Interleukin-6 (IL-6) and Glycoprotein Acetyls (GlycA).'Can omega-3s be inflammatory?The researchers found that in both cohorts, both omega-3 and omega-6 levels were associated with higher levels of GlycA.Holland told Medical News Today:'Surprisingly, the results showed that both omega-3 and omega-6 fatty acids were associated with higher levels of a marker called GlycA (a novel inflammatory marker), which reflects low-grade chronic inflammation. This was unexpected, especially for omega-3s, which are widely promoted as anti-inflammatory.''Omega-3s are found in dark fatty fish, like salmon and sardines, and in plant-based foods like flaxseeds, chia seeds, and walnuts. Most people think of them as calming to the immune system. Yet in this study, higher omega-3 levels were linked to more inflammation, not less, at least when GlycA was used as the measurement,' he added.Omega-6 to omega-3 fatty acid ratio could be keyIn the ALSPAC cohort, there was a consistent association between a higher omega-6:omega-3 ratio and all three inflammatory biomarkers.Holland told us that this ratio is influenced by our changed diet:'This [finding] supports earlier findings that it's not just about how much omega-3 you consume; it's about how balanced your overall intake is. In fact, research highlights how this ratio has shifted dramatically in recent history. A century ago, people typically consumed a 4:1 ratio of omega-6 to omega-3. Today, due to modern diets rich in industrial seed oils, that ratio has ballooned to around 15:1 to 20:1. This shift creates a pro-inflammatory environment that could be contributing to chronic diseases, allergies, and autoimmune disorders.''Our findings suggest that it's not as simple as 'omega-3 is anti-inflammatory, and omega-6 is pro-inflammatory'. Just increasing the consumption of omega-3 through diet or supplements might not be enough to lower inflammation. Instead, our results suggest that it might be more useful to look at the balance or ratio between omega-6 and omega-3 in the diet. Improving the balance between the two fats could be a better method for people who want to reduce inflammation in their bodies.'— Daisy CrickThe link between fatty acids and health is complexAlthough the study found an association between PUFAs and some of the 3 biomarkers, the authors emphasize that different biomarkers measure different aspects of inflammation, so by assessing only 3 biomarkers, they may have missed some important effects of PUFAs on inflammation. Further research using additional biomarkers is needed to better understand the relationship between PUFAs and inflammation.Holland told MNT that these findings should lead to further research: 'It is important to remember that the study measured just three inflammatory markers. The immune system is incredibly complex, and omega fatty acids might influence other pathways that weren't captured here. For example, omega-3s might still help resolve short-term inflammation or protect against specific diseases, even if they raise GlycA slightly. More research using a broader range of immune biomarkers will help clarify this relationship.'Despite this limitation, the findings highlight that there may be more to the relationship between fatty acids and health than previously thought.'The relationship between fatty acids and inflammation is complex and our findings only tell part of the story. Although we show that omega-3 fats are associated with increases in some biomarkers of inflammation, it does not rule out other potential beneficial effects of these fatty acids in the diet.'— Daisy Crick
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

First new treatment for advanced bladder cancer in decades given green light
First new treatment for advanced bladder cancer in decades given green light

The Independent

timean hour ago

  • The Independent

First new treatment for advanced bladder cancer in decades given green light

A new treatment for advanced bladder cancer which doubles survival time has been given the green light for NHS use. Experts said the approval of the new treatment combination would bring a 'fundamental shift' in care for patients with late-stage disease, saying that until now, the treatment for advanced bladder cancer had not significantly changed since the 1980s. They said there had been real 'unmet need' for patients with advanced disease, with some 29% of people diagnosed with stage 4 cancer – when the cancer has spread to other parts of the body – surviving for a year after diagnosis. It is estimated that 1,250 people a year could benefit from the treatment. The new treatment combination includes enfortumab vedotin, an antibody-drug which is also known as Padcev, made by Astellas and Pfizer – with pembrolizumab, a drug known as a PD-L1 inhibitor, also known as Keytruda, which is made by Merck. Clinical trials suggest that the treatment combination, when tested against platinum-based chemotherapy, led to improved survival for patients. 'Prior to the EV-302 clinical trial, the treatment of advanced bladder cancer treatment hadn't significantly changed since the 1980s,' Professor Thomas Powles, director of Barts Cancer Institute Biomedical Research Centre (QMUL), UK and primary investigator on the trial, said. 'This guidance will fundamentally reshape first-line treatment for eligible patients.' Trial data indicated that patients who took the treatment combination survived for an average of 33.8 months compared to 15.9 months with chemotherapy. Researchers also measured the amount of time people survived without their disease worsening – also known as progression-free survival – and found that people on the combination treatment had just more than a year of progression-free survival compared to half-a-year for those on standard treatment. Three in 10 (30%) patients had a so-called 'complete response' when getting the combination treatment – meaning there was no evidence of cancer remaining. This was compared to 14.5% of those who received chemotherapy. One patient said that taking part in the trial had given him more time with his grandson. Martyn Hewett, 75, from Stratford, east London, received the combination treatment on a trial at Barts Health NHS Trust after surgery to remove his tumours failed. He said: 'I feel very, very lucky, because if I hadn't been on this trial, I imagine I would be dead by now. 'Immediately after the operation that failed, I asked the doctor what the prognosis was, and he said, most people in your position live for a year, and now, three-and-a-half years later here I am. 'I am going to have an extra few years to see my grandson grow up – and maybe even be around to see him get married.' The treatment combination will now be available for NHS patients in England following the approval from the National Institute for Health and Care Excellence (Nice) for patients with 'unresectable or metastatic urothelial cancer for people who are eligible for platinum-containing chemotherapy' and is given as an IV infusion in hospitals or clinics. Dr Timir Patel, medical director of Astellas UK, said: 'The guidance from Nice is excellent news for patients. 'Advanced bladder cancer is in an area where there is a real unmet need. 'This combination therapy changes the standard of care for doctors and their patients.' Helen Knight, director of medicines evaluation at Nice, said: 'This is a highly promising and effective new drug, with clinical trial results highlighting the tremendous difference it could make to the length and quality of people's lives. 'Advanced bladder cancer is a devastating condition which can have a substantial impact on people's daily lives, often leading to them struggling to work, travel or maintain physical activity.' Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'This is one of the most hopeful advances in decades for people with bladder cancer who will now be offered a treatment that can almost double their chances of survival, helping thousands to live longer and giving them more precious moments with their loved ones. 'Bladder cancer is often difficult to treat once it has spread, but this new therapy is the first one in years to really help stop the disease in its tracks, and our rollout to NHS patients will make a huge difference to the lives of those affected and their families.' Jeannie Rigby, chief executive of charity Action Bladder Cancer UK, said: 'This new drug has the potential to increase how long people have before their cancer gets worse and how long they live compared with the current, limited, treatment choices available.' Around 18,000 people in England are diagnosed with bladder cancer each year.

New advanced bladder cancer treatment can ‘double chances of survival'
New advanced bladder cancer treatment can ‘double chances of survival'

The Independent

time2 hours ago

  • The Independent

New advanced bladder cancer treatment can ‘double chances of survival'

A new treatment for advanced bladder cancer which doubles survival time has been approved for NHS use. The treatment for advanced bladder cancer had not significantly changed since the 1980s. Now, experts say the approval of the new treatment combination would bring a 'fundamental shift' in care for patients with late-stage disease. They said there had been real 'unmet need' for patients with advanced disease, with some 29 per cent of people diagnosed with stage 4 cancer – when the cancer has spread to other parts of the body – surviving for a year after diagnosis. It is estimated that 1,250 people a year could benefit from the treatment. The new treatment combination includes enfortumab vedotin, an antibody-drug which is also known as Padcev, made by Astellas and Pfizer – with pembrolizumab, a drug known as a PD-L1 inhibitor, also known as Keytruda, which is made by Merck. Clinical trials suggest that the treatment combination, when tested against platinum-based chemotherapy, led to improved survival for patients. 'Prior to the EV-302 clinical trial, the treatment of advanced bladder cancer treatment hadn't significantly changed since the 1980s,' Professor Thomas Powles, director of Barts Cancer Institute Biomedical Research Centre (QMUL), UK and primary investigator on the trial, said. 'This guidance will fundamentally reshape first-line treatment for eligible patients.' Trial data indicated that patients who took the treatment combination survived for an average of 33.8 months compared to 15.9 months with chemotherapy. Researchers also measured the amount of time people survived without their disease worsening – also known as progression-free survival – and found that people on the combination treatment had just more than a year of progression-free survival compared to half-a-year for those on standard treatment. Three in 10 (30 per cent) patients had a so-called 'complete response' when getting the combination treatment – meaning there was no evidence of cancer remaining. This was compared to 14.5 per cent of those who received chemotherapy. One patient said that taking part in the trial had given him more time with his grandson. Martyn Hewett, 75, from Stratford, east London, received the combination treatment on a trial at Barts Health NHS Trust after surgery to remove his tumours failed. He said: 'I feel very, very lucky, because if I hadn't been on this trial, I imagine I would be dead by now. 'Immediately after the operation that failed, I asked the doctor what the prognosis was, and he said, most people in your position live for a year, and now, three-and-a-half years later here I am. 'I am going to have an extra few years to see my grandson grow up – and maybe even be around to see him get married.' The treatment combination will now be available for NHS patients in England following the approval from the National Institute for Health and Care Excellence (Nice) for patients with 'unresectable or metastatic urothelial cancer for people who are eligible for platinum-containing chemotherapy' and is given as an IV infusion in hospitals or clinics. Dr Timir Patel, medical director of Astellas UK, said: 'The guidance from Nice is excellent news for patients. 'Advanced bladder cancer is in an area where there is a real unmet need. 'This combination therapy changes the standard of care for doctors and their patients.' Helen Knight, director of medicines evaluation at Nice, said: 'This is a highly promising and effective new drug, with clinical trial results highlighting the tremendous difference it could make to the length and quality of people's lives. 'Advanced bladder cancer is a devastating condition which can have a substantial impact on people's daily lives, often leading to them struggling to work, travel or maintain physical activity.' Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'This is one of the most hopeful advances in decades for people with bladder cancer who will now be offered a treatment that can almost double their chances of survival, helping thousands to live longer and giving them more precious moments with their loved ones. 'Bladder cancer is often difficult to treat once it has spread, but this new therapy is the first one in years to really help stop the disease in its tracks, and our rollout to NHS patients will make a huge difference to the lives of those affected and their families.' Jeannie Rigby, chief executive of charity Action Bladder Cancer UK, said: 'This new drug has the potential to increase how long people have before their cancer gets worse and how long they live compared with the current, limited, treatment choices available.' Around 18,000 people in England are diagnosed with bladder cancer each year.

Government urged to enforce a total ban on smacking of children
Government urged to enforce a total ban on smacking of children

The Independent

time2 hours ago

  • The Independent

Government urged to enforce a total ban on smacking of children

Campaigners have made a fresh call for laws to ban the smacking of children in England. It comes as belief among young adults that forceful actions against children has grown stronger in recent years, according to a new poll. Wales made any type of corporal punishment, including smacking, hitting, slapping and shaking, illegal in March 2022, while Scotland introduced a similar ban in November 2020. But it is not completely outlawed in England and Northern Ireland. According to the Children Act 2004, it is unlawful to hit your child, except where it is 'reasonable punishment', and this is judged on a case-by-case basis. New polling for the NSPCC, carried out by YouGov, suggests around eight in 10 people (82 per cent) aged between 18 and 24 believe it is unacceptable for a parent to use force, however slight, against a child. This is an increase from 64 per cent of young adults who thought it was unacceptable when polled in 2023. Among parents specifically, the figures have remained high in recent years, with the latest polling showing 81 per cent felt this way, up slightly from 80 per cent last year and from 76 per cent in 2022. YouGov surveyed 3,800 adults across England in July, of which 749 were parents with a child under 18 and 198 were aged 18 to 24 years old. Of all adults surveyed, 71 per cent said they believe physical punishment against a child is unacceptable, up from 67 per cent in 2023. Earlier this year leading health experts came together to urge parliamentarians to give children the 'fundamental right to safety and protection' by backing a smacking ban. The children's doctors and psychiatrists said decades of research showed the 'detrimental effects of physical punishment'. On the latest figures, NSPCC chief executive Chris Sherwood said: 'Parents and young people are telling us loud and clear that they don't want physical punishment to be a part of anyone's childhood. 'Parents know their children and what works best for them. It is therefore crucial their experiences and opinions are not ignored or undermined, but act as a wake-up call. 'As parliamentarians continue to debate the Children's Wellbeing and Schools Bill, we urge them to change the law to better reflect public attitudes to violence against children and ensure no childhood has to be tainted by physical punishment again.' In June, as part of debate on the Bill, Conservative peer Lord Jackson of Peterborough warned that introducing a smacking ban in England would be 'disproportionate and heavy-handed'. He argued 'reasonable chastisement' was harmless and calls to abolish it as a defence for punishing a child risked 'criminalising good and caring parents, as well as overloading children's services departments'. But, in the wake of the murder of 10-year-old Sara Sharif in Woking in 2023, the UK's four children's commissioners jointly called for a wholesale smacking ban, describing the current situation where there is a legal defence in some nations as 'outdated and morally repugnant'. Sara's father – jailed for life in December 2024 alongside her stepmother for the little girl's murder – had claimed in a call to police after fleeing England that he 'did legally punish' his daughter and that he 'beat her up too much'. The children's commissioners insisted 'loving, well-meaning' parents have no need to be concerned about a change in the law. Lynn Perry, chief executive of Barnardo's, said: 'Violence against children is unacceptable – and yet children continue to have less legal protection against physical assault than adults. That cannot be right. This new data shows that most parents agree. 'Physical punishment like smacking is harmful to a child's health and development, and there's strong evidence that it influences their attitudes toward violence. At Barnardo's, we see first-hand how vital it is for children to feel safe and nurtured by those around them and to develop positive, healthy relationships. 'We have long campaigned for a change in the law to give children equal protection from assault and continue to call for action. It's time for all children to be legally protected from all physical punishment everywhere in the UK.' Commenting on the poll, Professor Andrew Rowland, officer for child protection at the Royal College of Paediatrics and Child Health, said: 'This latest research makes it clear that physical punishment has no place in modern parenting. 'Health professionals stand firmly with parents and young people in recognising that physical punishment is not only outdated and unjust, but also harmful to children's health and wellbeing. 'We urge the government to listen to parents, young people, health professionals and the wider public and to finally remove the outdated and unfair 'reasonable punishment' defence.' A Department for Education spokesperson said: 'The landmark Children's Wellbeing and Schools Bill, a key part of our plan for change, represents the most transformative piece of child protection legislation in a generation, including wholesale reform of the children's social care system and better information sharing between education, health, and social workers to stop vulnerable children falling through the cracks. 'While we are looking closely at the legal changes made in Wales and Scotland in relation to smacking, we have no plans to legislate at this stage.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store